The European Medicine Agency (EMA) on Monday approved the COVID-19 vaccine developed by BioNTech and Pfizer to be used in the European Union.
“I’m delighted to be here and to announce that that EMA Scientific Committee met today and recommended a conditional marketing authorization in the EU for the vaccine developed by BioNTech and Pfizer,” Emer Cooke, the EMA executive director, said in a news conference.
Cooke said the clinical trials showed the vaccine was effective at preventing COVID-19 in people from 16 years of age and the EMA’s scientific opinion paves the way for the first marketing authorization of a COVID-19 vaccine in the EU, “with the corresponding safeguards, controls, and obligations.”
“It will be valid in all 27 member states at the same time, and it provides them with a firm scientific foundation for the rollout of their vaccination programs, and a continuing framework for control and supervision of the vaccines,” she added.
Copyright 2022 Anadolu Agency. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.